Q-omics provides the consensus-scored UTS2B profile across patient tissues and cancer cell-line models. UTS2B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, UTS2B is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, UTS2B RNA expression shows 18,337 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, COAD, and UVM as cancer lineages where UTS2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UTS2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UTS2B survival associations across molecular data types. UTS2B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UTS2B RNA expression–survival associations across cancer types. High UTS2B expression shows unfavorable associations in LIHC and ACC, but favorable associations in HNSC, LUAD, ESCA and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for UTS2B RNA expression.
This table summarizes UTS2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for UTS2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UTS2B shows lower tumor expression in COAD, THCA, BRCA, KIRC, UCEC and KICH. The COAD box plot shows higher UTS2B RNA expression in normal versus tumor tissue (log2 FC = −0.374, t-test p < 0.001).
This table shows molecular features associated with UTS2B in patient tissues and cancer cell lines. In patient samples, UTS2B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, UTS2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and BREAST.
